Day: July 14, 2025

Inavosilib in PIK3CA-mutated advanced breast cancer

Inavosilib plus palbociclib-fulvestrant led to a significant survival benefit versus placebo plus palbociclib-fulvestrant in PIK3CA-mutated advanced breast cancer